EUROAPI, a company focused on reinventing active ingredient solutions, announced a €50 million investment for the installation of a new state-of-the-art production plant at its Budapest site. The project will be focused on the debottlenecking of the current capacity and the construction of new multi-purpose manufacturing equipment that will more than double the overall prostaglandin capacity of the Budapest site by 2027 in two phases: 2023-2025 (approximately 2/3 of the total investment) and 2026-2027.

Prostaglandin is one of the most dynamic components of the active pharmaceutical ingredient (API) market, with a ~€5 billion annual drug product sales market, expected to grow at 5-7% annually (CAGR1) between 2022 and 2027.

In a statement, EUROAPI said that it is the only Western supplier with a complete portfolio of prostaglandins and a fully integrated production site located in Europe. The project aims to bolster EUROAPI’s Hungarian operations and reinforce the company’s commitment to serving the needs of its clients in differentiated segments of health products.

“EUROAPI is positioned as the only Western prostaglandin supplier with a complete prostaglandin portfolio and a fully backward-integrated production located in the heart of Europe,” said Karl Rotthier, CEO of EUROAPI. “This key investment in Budapest will enable us to increase our productivity and meet the growing demand in a dynamic prostaglandin market, growing at 5-7% per annum.”